
via Rensselaer Polytechnic Institute
Heparin, a common anticoagulant, could also form the basis of a viral trap for SARS-CoV-2
In a test of antiviral effectiveness against the virus that causes COVID-19, an extract from edible seaweeds substantially outperformed remdesivir, the current standard antiviral used to combat the disease. Heparin, a common blood thinner, and a heparin variant stripped of its anticoagulant properties, performed on par with remdesivir in inhibiting SARS-CoV-2 infection in mammalian cells.
Published online today in Cell Discovery, the research is the latest example of a decoy strategy researchers from the Center for Biotechnology and Interdisciplinary Studies (CBIS) at Rensselear Polytechnic Institute are developing against viruses like the novel coronavirus that spawned the current global health crisis.
The spike protein on the surface of SARS-CoV-2 latches onto the ACE-2 receptor, a molecule on the surface of human cells. Once secured, the virus inserts its own genetic material into the cell, hijacking the cellular machinery to produce replica viruses. But the virus could just as easily be persuaded to lock onto a decoy molecule that offers a similar fit. The neutralized virus would be trapped and eventually degrade naturally.
Previous research has shown this decoy technique works in trapping other viruses, including dengue, Zika, and influenza A.
“We’re learning how to block viral infection, and that is knowledge we are going to need if we want to rapidly confront pandemics,” said Jonathan Dordick, the lead researcher and a professor of chemical and biological engineering at Rensselaer Polytechnic Institute. “The reality is that we don’t have great antivirals. To protect ourselves against future pandemics, we are going to need an arsenal of approaches that we can quickly adapt to emerging viruses.”
The Cell Discovery paper tests antiviral activity in three variants of heparin (heparin, trisulfated heparin, and a non-anticoagulant low molecular weight heparin) and two fucoidans (RPI-27 and RPI-28) extracted from seaweed. All five compounds are long chains of sugar molecules known as sulfated polysaccharides, a structural conformation that the results of a binding study published earlier this month in Antiviral Research suggested as an effective decoy.
The researchers performed a dose response study known as an EC50 — shorthand for the effective concentration of the compound that inhibits 50% of viral infectivity — with each of the five compounds on mammalian cells. For the results of an EC50, which are given in a molar concentration, a lower value signals a more potent compound.
RPI-27 yielded an EC50 value of approximately 83 nanomolar, while a similar previously published and independent in vitro test of remdesivir on the same mammalian cells yielded an EC50 of 770 nanomolar. Heparin yielded an EC50 of 2.1 micromolar, or about one-third as active as remdesivir, and a non-anticoagulant analog of heparin yielded an EC50 of 5.0 micromolar, about one-fifth as active as remdesivir.
A separate test found no cellular toxicity in any of the compounds, even at the highest concentrations tested.
“What interests us is a new way of getting at infection,” said Robert Linhardt, a Rensselaer professor of chemistry and chemical biology who is collaborating with Dordick to develop the decoy strategy. “The current thinking is that the COVID-19 infection starts in the nose, and either of these substances could be the basis for a nasal spray. If you could simply treat the infection early, or even treat before you have the infection, you would have a way of blocking it before it enters the body.”
Dordick added that compounds from seaweed “could serve as a basis for an oral delivery approach to address potential gastrointestinal infection.”
In studying SARS-CoV-2 sequencing data, Dordick and Linhardt recognized several motifs on the structure of the spike protein that promised a fit compatible with heparin, a result borne out in the binding study. The spike protein is heavily encrusted in glycans, an adaptation that protects it from human enzymes which could degrade it, and prepares it to bind with a specific receptor on the cell surface.
“It’s a very complicated mechanism that we quite frankly don’t know all the details about, but we’re getting more information,” said Dordick. “One thing that’s become clear with this study is that the larger the molecule, the better the fit. The more successful compounds are the larger sulfated polysaccharides that offer a greater number of sites on the molecules to trap the virus.”
Molecular modeling based on the binding study revealed sites on the spike protein where the heparin was able to interact, raising the prospects for similar sulfated polysaccharides.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Coronavirus decoy strategy
- New Report -Decoy Flares Market Size 2023 NEW REPORT CAGR with Regional Development, Deployment, Growth Factor, Production Cost
Mar 24, 2023 (The Expresswire) -- Global Decoy Flares Market research report ... Furthermore, the report provides strategies for companies to overcome threats posed by COVID-19. Technological ...
- Newly-revealed coronavirus data has reignited a debate over the virus’s origins
Samples kept from view since they were collected in 2020 highlight the possible role of raccoon dogs, and have kicked off plenty of drama this week.
- COVID-19 pandemic 'most likely' started in Wuhan lab, FBI Director Christopher Wray says
WASHINGTON – The COVID-19 pandemic "most likely" started after a Wuhan laboratory leak in China, FBI Director Christopher Wray said Tuesday. He publicly confirmed the bureau's assessment of ...
- The Covid-19 Pandemic
With the acute phase of the Covid-19 pandemic fading even as the coronavirus persists and evolves, a new normal is taking shape around the world. A lab leak was once dismissed by many as a ...
- Decoy Flares Market Outlook and Forecast to 2028 with Top Countries Data
The "Decoy Flares Market" Study Describes how the technology industry is evolving and how major and emerging players in ...
Go deeper with Google Headlines on:
Coronavirus decoy strategy
[google_news title=”” keyword=”coronavirus decoy strategy” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Heparin
- Global "Heparin Market" Trend & Forecast by 2031
Report Highlights with 107 pages: -"The global Heparin market size was valued at USD 7293.0 million in 2022 and is ...
- Heparin Sodium Market Top Players and Forecast till 2031
The "Heparin Sodium Market" Study Describes how the technology industry is evolving and how major and emerging players ...
- Antiphospholipid Syndrome : What is it & treatments
Overview An autoimmune disorder in which the immune system mistakenly produces antibodies and attacks the normal proteins in the blood. This results in increase risk of blood clots in legs, kidneys, ...
- Activated Partial Thromboplastin Time versus Antifactor Xa Heparin Assay in Monitoring Unfractionated Heparin by Continuous Intravenous Infusion
Background: Unfractionated heparin (UFH) has been used clinically for 5 decades. Despite being a cornerstone of anticoagulation, UFH is limited by its unpredictable pharmacokinetic profile ...
- Trial Suggests Anticoagulation 'Sweet Spot' for COVID in the ICU
No anticoagulation strategy came out a clear winner for hard outcomes in a hypoxic and largely critically ill COVID-19 patient population, although higher-dose prophylaxis did decrease risk of ...
Go deeper with Google Headlines on:
Heparin
[google_news title=”” keyword=”Heparin” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]